Investigating brain activity in mild cognitive impairment related to Parkinson's disease
Electrophysiological Signature of Mild Cognitive Impairment and Its Relationship with Parkinson's Disease: a High-density EEG Investigation
This study is trying to see how brain activity is different in people with Parkinson's disease who have mild cognitive impairment compared to those who don't and healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 42 (estimated) |
| Ages | 50 Years to 90 Years |
| Sex | All |
| Sponsor | IRCCS San Camillo, Venezia, Italy Academic / other |
| Locations | 1 site (Lido, Italy) |
| Trial ID | NCT06640673 on ClinicalTrials.gov |
What this trial studies
This study examines the neural correlates of Mild Cognitive Impairment (MCI) in patients with Parkinson's disease (PD) by utilizing high-density electroencephalography (hdEEG) to measure electro-cortical activity. A total of 42 participants will be divided into three groups: healthy controls, PD patients with MCI, and PD patients without MCI. Participants will undergo neuropsychological evaluations and hdEEG recordings during resting states and cognitive tasks, with additional structural MRI data to analyze network connectivity. The goal is to identify links between cognitive and motor impairments and the electrophysiological signatures of MCI in PD.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Parkinson's disease, particularly those exhibiting mild cognitive impairment or healthy controls.
Not a fit: Patients with severe dementia or those unable to walk independently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of cognitive impairments in Parkinson's disease, leading to better diagnostic and therapeutic strategies.
How similar studies have performed: While there have been studies exploring cognitive impairments in Parkinson's disease, the specific use of high-density EEG in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Upper score \>24 MMSE or \>15.5 Moca * If taking medications, taking stable doses for at least 4 weeks prior to the inclusion visit - of anticholinesterase drugs (donepezil, memantine, rivastigmine, ...) or antidepressants (SSRIs, tricyclics, SNARI, ...) or Levodopa. * Having signed the informed consent Exclusion Criteria: * Subjects with severe dementia ( MMSE \< 24 ) * Lower score \<15.5 Moca * Subjects on antipsychotic treatment for less than 3 months * Subjects with uncontrolled comorbidities * Subjects with metal prostheses or dentures and in general conditions for which MRI examinations are prevented. * Subjects with an inability to walk independently.
Where this trial is running
Lido, Italy
- IRCCS San Camillo S.R.L — Lido, Italy, Italy (Recruiting)
Study contacts
- Principal investigator: francesca burgio, phd — San Camillo IRCCS
- Study coordinator: Francesca Burgio, PhD
- Email: francesca.burgio@hsancamillo.it
- Phone: +390412207536
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.